Kala Pharmaceuticals Inc
NASDAQ:KALA
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
N
|
Nutroganics Inc
OTC:NUTTQ
|
US |
Kala Pharmaceuticals Inc
Net Income (Common)
Kala Pharmaceuticals Inc
Net Income (Common) Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Net Income (Common) | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Kala Pharmaceuticals Inc
NASDAQ:KALA
|
Net Income (Common)
-$35.8m
|
CAGR 3-Years
23%
|
CAGR 5-Years
18%
|
CAGR 10-Years
N/A
|
|
|
Johnson & Johnson
NYSE:JNJ
|
Net Income (Common)
$21B
|
CAGR 3-Years
18%
|
CAGR 5-Years
7%
|
CAGR 10-Years
3%
|
|
|
Bristol-Myers Squibb Co
NYSE:BMY
|
Net Income (Common)
$26.3m
|
CAGR 3-Years
-84%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
-34%
|
|
|
Pfizer Inc
NYSE:PFE
|
Net Income (Common)
$7.8B
|
CAGR 3-Years
-37%
|
CAGR 5-Years
-3%
|
CAGR 10-Years
1%
|
|
|
Merck & Co Inc
NYSE:MRK
|
Net Income (Common)
$8.9B
|
CAGR 3-Years
-12%
|
CAGR 5-Years
5%
|
CAGR 10-Years
7%
|
|
|
Eli Lilly and Co
NYSE:LLY
|
Net Income (Common)
$25.3B
|
CAGR 3-Years
64%
|
CAGR 5-Years
33%
|
CAGR 10-Years
27%
|
|
Kala Pharmaceuticals Inc
Glance View
Kala Pharmaceuticals, Inc. is a biopharmaceutical company. The company is headquartered in Arlington, Massachusetts and currently employs 192 full-time employees. The company went IPO on 2017-07-20. The firm's product candidate includes EYSUVIS (loteprednol etabonate ophthalmic suspension) 0.25% and INVELTYS (loteprednol etabonate ophthalmic suspension) 1%. Its EYSUVIS product is a short-term (up to two weeks) treatment of the signs and symptoms of dry eye disease. INVELTYS product is a topical twice-a-day ocular steroid for the treatment of post-operative inflammation and pain following ocular surgery. The firm's AMPPLIFY technology uses selectively-sized nanoparticles that each have a coating. The firm also has a pipeline of development programs, including a clinical-stage secretome product candidate, KPI-012, initially targeting persistent corneal epithelial defects (PCED) and multiple new chemical entity (NCE) preclinical development programs targeted to address unmet medical needs.
See Also
What is Kala Pharmaceuticals Inc's Net Income (Common)?
Net Income (Common)
-35.8m
USD
Based on the financial report for Sep 30, 2025, Kala Pharmaceuticals Inc's Net Income (Common) amounts to -35.8m USD.
What is Kala Pharmaceuticals Inc's Net Income (Common) growth rate?
Net Income (Common) CAGR 5Y
18%
Over the last year, the Net Income (Common) growth was 8%. The average annual Net Income (Common) growth rates for Kala Pharmaceuticals Inc have been 23% over the past three years , 18% over the past five years .
